azathioprine has been researched along with Chronic Kidney Diseases in 11 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Azathioprine (AZA) was added for remission-maintenance therapy." | 5.48 | Neutropenia related to an azathioprine metabolic disorder induced by an inosine triphosphate pyrophosphohydrolase (ITPA) gene mutation in a patient with PR3-ANCA-positive microscopic polyangiitis . ( Hasegawa, T; Honda, K; Ishizuka, S; Ito, S; Kobayashi, A; Komine, K; Kubota, T; Motoi, Y; Niikura, T; Saito, Z; Sasaki, T; Yamamoto, H; Yokoo, T, 2018) |
| " The aim of this study was to evaluate the outcome of a conversion from CNI-based immunosuppressive protocol to sirolimus (SRL) in recipients with graft in chronic kidney disease (CKD) grade III and proteinuria below 500 mg/day." | 3.79 | Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011. ( Aleksić, P; Drasković-Pavlović, B; Dujić, A; Hrvacević, R; Ignjatović, L; Jovanović, D; Karan, Z; Kovacević, Z; Maksić, D; Rabrenović, V; Tomić, A; Vavić, N, 2013) |
| "Azathioprine (AZA) was added for remission-maintenance therapy." | 1.48 | Neutropenia related to an azathioprine metabolic disorder induced by an inosine triphosphate pyrophosphohydrolase (ITPA) gene mutation in a patient with PR3-ANCA-positive microscopic polyangiitis . ( Hasegawa, T; Honda, K; Ishizuka, S; Ito, S; Kobayashi, A; Komine, K; Kubota, T; Motoi, Y; Niikura, T; Saito, Z; Sasaki, T; Yamamoto, H; Yokoo, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Phanish, MK | 1 |
| Hull, RP | 1 |
| Andrews, PA | 1 |
| Popoola, J | 1 |
| Kingdon, EJ | 1 |
| MacPhee, IAM | 1 |
| Rasheed, N | 1 |
| Ahuja, R | 1 |
| Borneo, H | 1 |
| Tziastoudi, M | 1 |
| Pissas, G | 1 |
| Raptis, G | 1 |
| Cholevas, C | 1 |
| Eleftheriadis, T | 1 |
| Dounousi, E | 1 |
| Stefanidis, I | 1 |
| Theoharides, TC | 1 |
| Palamuthusingam, D | 1 |
| Mantha, M | 1 |
| Dheda, S | 1 |
| Honda, K | 1 |
| Kobayashi, A | 1 |
| Niikura, T | 1 |
| Hasegawa, T | 1 |
| Saito, Z | 1 |
| Ito, S | 1 |
| Sasaki, T | 1 |
| Komine, K | 1 |
| Ishizuka, S | 1 |
| Motoi, Y | 1 |
| Kubota, T | 1 |
| Yamamoto, H | 1 |
| Yokoo, T | 1 |
| Lopez-Lopez, I | 1 |
| Rodelo-Haad, C | 1 |
| Agüera, ML | 1 |
| Cabello-Jabalquinto, R | 1 |
| Esquivias-Motta, E | 1 |
| Navarro, MD | 1 |
| Aljama, P | 1 |
| Rodriguez-Benot, A | 1 |
| Ignjatović, L | 1 |
| Hrvacević, R | 1 |
| Jovanović, D | 1 |
| Kovacević, Z | 1 |
| Vavić, N | 1 |
| Rabrenović, V | 1 |
| Tomić, A | 1 |
| Aleksić, P | 1 |
| Drasković-Pavlović, B | 1 |
| Dujić, A | 1 |
| Karan, Z | 1 |
| Maksić, D | 1 |
| Jones, RB | 1 |
| Furuta, S | 1 |
| Tervaert, JW | 1 |
| Hauser, T | 1 |
| Luqmani, R | 1 |
| Morgan, MD | 1 |
| Peh, CA | 1 |
| Savage, CO | 1 |
| Segelmark, M | 1 |
| Tesar, V | 1 |
| van Paassen, P | 1 |
| Walsh, M | 1 |
| Westman, K | 1 |
| Jayne, DR | 1 |
| Parodis, I | 1 |
| Ding, H | 1 |
| Zickert, A | 1 |
| Arnaud, L | 1 |
| Larsson, A | 1 |
| Svenungsson, E | 1 |
| Mohan, C | 1 |
| Gunnarsson, I | 1 |
| Pham, PT | 1 |
| Pham, PC | 1 |
| Edwards, NL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis[NCT02626845] | Phase 4 | 3 participants (Actual) | Interventional | 2015-12-31 | Terminated (stopped due to Slow recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for azathioprine and Chronic Kidney Diseases
| Article | Year |
|---|---|
A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease.
Topics: Azathioprine; Cyclosporine; Humans; Pharmacogenomic Testing; Pharmacogenomic Variants; Polymorphism, | 2021 |
1 trial available for azathioprine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Der | 2015 |
9 other studies available for azathioprine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
Topics: Adult; Aged; Azathioprine; Basiliximab; Drug Administration Schedule; Female; Glucocorticoids; Graft | 2020 |
Polyangiitis overlap syndrome: a novel presentation of microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis.
Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Churg-Strauss Syndrome; Cyclophosphamide; Fema | 2021 |
HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis.
Topics: Aged; Anti-Inflammatory Agents; Azathioprine; Diabetes Mellitus, Type 2; Fatal Outcome; Female; Hepa | 2017 |
Neutropenia related to an azathioprine metabolic disorder induced by an inosine triphosphate pyrophosphohydrolase (ITPA) gene mutation in a patient with PR3-ANCA-positive microscopic polyangiitis
.
Topics: Aged; Azathioprine; Humans; Male; Microscopic Polyangiitis; Mutation; Neutropenia; Pyrophosphatases; | 2018 |
Administration of mycophenolic acid is not associated with malformations in descendants from kidney transplanted males.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Fertilization; Graft Rejection; Humans; Immu | 2018 |
Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Topics: Adult; Azathioprine; Biomarkers; Calcineurin Inhibitors; Creatinine; Cytomegalovirus Infections; Fem | 2013 |
Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Azathioprine; Biomarkers; Cohor | 2017 |
The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
Topics: Adolescent; Adult; Aged; Azathioprine; Cyclosporine; Female; Follow-Up Studies; Glomerular Filtratio | 2012 |
Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Contraindications; Drug Interact | 2006 |